Respiratory Pharmacology 2 Flashcards

1
Q

What are the reliever drugs for asthma?

A
  • Β-2 agonists
  • methylxanthines
  • Anti-muscarinics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the preventer drugs for asthma?

A
  • Corticosteroids
  • Cromones
  • Anti-leukotrienes
  • Anti-IgE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe cromones as preventers

A
  • Sodium cromoglycate (Intal)
  • Nedocromil sodium (Tilade)
  • Dry inhaler for prophylaxis
  • Eye and nasal drops
  • Most effective inchildren
  • Excellent safety profile
  • Short half-life- 4x daily
  • More times taken, less compliant patient will be to complex medication routine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe the arachidonic acid cascade

A
  • Arachidonic acid
  • Cyclo-oxygenase–> prostaglandins, thromboxane and prostacyclin
  • 5-lipoxygenase–> LTA4
  • -> Cys-LT–> receptors –> bronchoconstriction, eosinophil recruitment, mucous secretion microvascular leak
  • -> LTB4
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the use of anti-leukotrienes as preventers

A
  • Target- 5-LO inhibitor- Zileurton
  • Common receptor antagonist- Montelukast and Zadirlukast
  • Antagonists of the Cys-LT receptors on smooth muscle and eosinophils
  • Oral prophylaxis for persistent asthma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the effect of anti-leukotrienes as preventers?

A
  • Bronchodilation- reduces frequency and severity of asthma attacks
  • Anti-inflammatory- reduces eosinophilia
  • Reduces comorbidities- allergic rhinitis
  • Paediatric formulations- inhalers might be difficult for them to use
  • Generally safe with minimal side effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the use of Anti-IgEs as preventers

A
  • Omalizumab (Xolair)
  • Humanised anti-IgE - 3% mouse protein
  • Binds IgE in plasma- does not cause mast cell degranulation
  • Moderate/severe uncontrolled asthma
  • Expensive and risk of anaphylaxis
  • Cumulative risk of anaphylaxis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Compare oral and inhaled therapy in terms of form of preparation and ideal pharmacokinetics

A
  • inhaled prep: aerosol/dry pwder
  • Oral prep: tablet/liquid
  • Ideal pharmacokinetics
  • -> inhaled: slow absorption from lung, rapid systemic clearance
  • -> Oral: good absorption, long systemic clearance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Compare oral and inhaled therapy in terms of dose and side effects

A
  • Inhaled: low direct dose to lung, low local side effects

- Oral: high dose, high side effects dependent on drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Compare oral and inhaled therapy in terms of access to lung and compliance

A
  • Inhaled: poor access, poor compliance

- Oral: good access, good compliance (easier to use)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Compare oral and inhaled therapy in terms of ease of use and effectiveness

A
  • Inhaled: difficult to use, effective in mild disease

- Oral- easy to use and effective, even in severe disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the treatment for acute severe asthma?

A
  • Status asthmaticus
  • Treatment
  • -> oxygen, nebuliser β-2-agonist, oral prednisolone or IV hydrocortisone
  • No improvement in 15-20 minutes
  • -> continue oxygen and β-2 agonist, Ipatropium and Mg2+, admit to hospital
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the principles of asthma therapy?

A
  • Mild/intermittent- short-acting β-2 agonist
  • Mild persistent- low-dose inhaled GCS
  • Moderate persistent
  • -> High dose inhaled GCS + salmeterol
  • -> Or, anti-LT or ipratrpium or the ophylline or cromone
  • Severe persistent–> oral GCS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why does asthma treatment fail?

A
  • Intentional non-adherence
  • -> patient feels better and stops taking medication
  • -> Dislike adverse effect
  • Unintentional non-adherence
  • -> Poor inhaler technique- may use them wrong
  • -> Complex dosing/drug regimen (forgetting to take it)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are asthma phenotypes?

A
  • Inflammation and symptoms
  • Inflammation predominant-> fever symptoms
  • Symptom predominant –> less inflammation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the pathogenesis of COPD? (mucus)

A
  • Increase in mucus production
  • -> Neutrophils recruited to lung
  • -> And, infection- release of elastase- breakdown of elastin, loss of elastic recoil and damage to alveoli
17
Q

What is the pathogenesis of COPD? (oxidative stress)

A
  • Irritant leads to oxidative stress, inactivation of α-1-antitrypsin
  • Regulates elastase activity
  • Results in the breakdown of elastin, loss of elastic recoil and damage to alveoli
18
Q

What is the treatment for COPD?

A
  • Encourage smoking cessation
  • Antibiotics for infection
  • Anti-Msc as bronchodilators
  • Β-agonists bronchodilators
  • Theophylline for cardo-toxicity
  • Steroids
  • Supp oxygen
  • Surgery-lung volume reduction
19
Q

Describe intentional non-adherence

A
  • Patient feels better
  • Side effects
  • Feels that drug is not working
  • Does not like formulation (e.g. dry powder inhaler)
  • Controversy surrounding drug in news
  • Attitude to new drug treatment
  • Cost
20
Q

How can adherence be recorded?

A
  • Diary report
  • Chronolog record
  • Doses taken at correct times
21
Q

Describe unintentional non-adherence

A
  • Poor inhaler technique

- Complex regimen

22
Q

How to improve poor inhaler technique?

A
  • Use of a spacer
  • Regular review of inhaler technique
  • Avoid getting dry powder inhalers moist
23
Q

How to improve complex drug regimen?

A
  • Simplify if possible

- Minimise effects on lifestyle

24
Q

How can adherence be improved?

A
  • Provide a written asthma plan and recognise effects of patient lifestyle
  • Regular follow up to ensure adherence